Drug Development Technology-Updates The latest content updates from the www.drugdevelopment-technology.com web site http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ Drug Development Technology-Updates http://www.drugdevelopment-technology.com/content/images/logo_big.gif Improving OMNISEC Results by Switching Mobile Phases http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/improving-omnisec-results-switching-mobile-phases/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/improving-omnisec-results-switching-mobile-phases/ Polylactic and polyglycolic acid are used for a number of applications including biomedical applications. Absorbable sutures, medical implant hardware, food packaging, and clothing all utilise these chemicals, which can also be used as a feedstock ma… Mon, 27 Mar 2017 08:00:00 GMT Cancer Research UK invests £10m in new pancreatic cancer trials http://www.drugdevelopment-technology.com/news/newscancer-research-uk-invests-10m-in-new-project-for-pancreatic-cancer-trials-5771162 http://www.drugdevelopment-technology.com/news/newscancer-research-uk-invests-10m-in-new-project-for-pancreatic-cancer-trials-5771162 Cancer Research UK has invested £10m in the PRECISION Panc project, designed to include a network of clinical trials for the treatment of pancreatic cancer. Sun, 26 Mar 2017 23:00:00 GMT Neuren reports positive top-line results from Phase II trial of trofinetide for Rett syndrome http://www.drugdevelopment-technology.com/news/newsneuren-reports-positive-top-line-results-from-phase-ii-trial-of-trofinetide-for-rett-syndrome-5771898 http://www.drugdevelopment-technology.com/news/newsneuren-reports-positive-top-line-results-from-phase-ii-trial-of-trofinetide-for-rett-syndrome-5771898 Australian-based biopharmaceutical firm Neuren Pharmaceuticals has reported positive top-line results from the Phase II clinical trial of trofinetide to treat girls with Rett syndrome. Sun, 26 Mar 2017 23:00:00 GMT CTSA programme sites sign NIH's SMART agreement for single IRB model http://www.drugdevelopment-technology.com/news/newsctsa-programme-sites-sign-nihs-smart-agreement-for-single-irb-model-5771150 http://www.drugdevelopment-technology.com/news/newsctsa-programme-sites-sign-nihs-smart-agreement-for-single-irb-model-5771150 All sites in the clinical and translational science awards (CTSA) programme have signed on to the National Institutes of Health's (NIH) National Center for Advancing Translational Sciences (NCATS) streamlined, multisite, accelerated resources for tri… Sun, 26 Mar 2017 23:00:00 GMT Deals this week: Heat Biologics, Bellicum Pharmaceuticals, SutroVax http://www.drugdevelopment-technology.com/news/newsdeals-this-week-heat-biologics-inc-bellicum-pharmaceuticals-inc-sutrovax-inc-5770612 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-heat-biologics-inc-bellicum-pharmaceuticals-inc-sutrovax-inc-5770612 US-based immuno-oncology company Heat Biologics intends to raise funds through an underwritten public offering of shares of its common stock, with Aegis Capital as the book-running manager. Fri, 24 Mar 2017 00:00:00 GMT Akashi to initiate HALO-DMD-04 trial of HT-100 to treat DMD http://www.drugdevelopment-technology.com/news/newsakashi-to-initiate-halo-dmd-04-trial-of-ht-100-to-treat-dmd-5769910 http://www.drugdevelopment-technology.com/news/newsakashi-to-initiate-halo-dmd-04-trial-of-ht-100-to-treat-dmd-5769910 Akashi Therapeutics is planning to initiate the HALO-DMD-04 clinical trial of HT-100 (delayed-release halofuginone) to treat patients with duchenne muscular dystrophy (DMD). Fri, 24 Mar 2017 00:00:00 GMT M&As this week: Zhejiang Jingxin Pharmaceutical, BioLineRx http://www.drugdevelopment-technology.com/news/newsmas-this-week-zhejiang-jingxin-pharmaceutical-biolinerx-ltd-5770934 http://www.drugdevelopment-technology.com/news/newsmas-this-week-zhejiang-jingxin-pharmaceutical-biolinerx-ltd-5770934 With the aim of growing its neurodegenerative diseases business, Zhejiang Jingxin Pharmaceutical has reached an agreement to acquire up to 5% stake in Israeli-based Pharma Two B. Fri, 24 Mar 2017 00:00:00 GMT Merrimack's Phase I trial of MM-310 starts patient enrolment to treat solid tumours http://www.drugdevelopment-technology.com/news/newsmerrimacks-phase-i-trial-of-mm-310-starts-enrollment-for-solid-tumour-pateints-5770111 http://www.drugdevelopment-technology.com/news/newsmerrimacks-phase-i-trial-of-mm-310-starts-enrollment-for-solid-tumour-pateints-5770111 US-based biopharmaceutical firm Merrimack Pharmaceuticals has started patient enrolment in a Phase I clinical trial of MM-310 for the treatment of solid tumours. Fri, 24 Mar 2017 00:00:00 GMT ePAT Automated Lab Reactor Optimised for 24/7 Data Capture http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/epat-automated-lab-reactor/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/epat-automated-lab-reactor/ Systag Systems presents ePAT, a cost-effective device for automation in the laboratory. Thu, 23 Mar 2017 16:48:00 GMT Benefits of Trehalose http://www.drugdevelopment-technology.com/downloads/whitepapers/organic/benefits-of-trehalose/ http://www.drugdevelopment-technology.com/downloads/whitepapers/organic/benefits-of-trehalose/ Products such as monoclonal antibodies (mAb), fusion proteins, peptides, vaccines, antibody drug conjugulates (ADC) and stem cells benefit from the stabilising effects of Trehalose. Thu, 23 Mar 2017 16:48:00 GMT Intec Pharma begins Phase I trial of AP-CBD / THC to treat low back pain and fibromyalgia http://www.drugdevelopment-technology.com/news/newsintec-pharma-begins-phase-i-trial-of-ap-cbdthc-to-treat-low-back-pain-and-fibromyalgia-5769329 http://www.drugdevelopment-technology.com/news/newsintec-pharma-begins-phase-i-trial-of-ap-cbdthc-to-treat-low-back-pain-and-fibromyalgia-5769329 Israeli-based biopharmaceutical firm Intec Pharma has begun a Phase I clinical trial of AP-CBD / THC for the treatment of multiple indications such as low back pain and fibromyalgia. Thu, 23 Mar 2017 00:00:00 GMT EnGeneIC begins dosing in Phase I trial of EDV nanocells to treat GBM in US http://www.drugdevelopment-technology.com/news/newsengeneic-begins-dosing-in-phase-i-trial-of-edv-nanocells-to-treat-gbm-in-us-5768903 http://www.drugdevelopment-technology.com/news/newsengeneic-begins-dosing-in-phase-i-trial-of-edv-nanocells-to-treat-gbm-in-us-5768903 Australian-based biopharmaceutical firm EnGeneIC has begun dosing patients in a Phase I clinical trial of its EDV nanocells for the treatment of recurrent glioblastoma multiforme (GBM) within adults in the US. Thu, 23 Mar 2017 00:00:00 GMT Galapagos begins Phase I trial of GLPG0367 to treat cystic fibrosis http://www.drugdevelopment-technology.com/news/newsgalapagos-begins-phase-i-trial-of-glpg0367-to-treat-cystic-fibrosis-5769626 http://www.drugdevelopment-technology.com/news/newsgalapagos-begins-phase-i-trial-of-glpg0367-to-treat-cystic-fibrosis-5769626 Belgium-based biopharmaceutical firm Galapagos has begun the Phase I clinical trial of GLPG3067 for the treatment of patients with cystic fibrosis (CF). Thu, 23 Mar 2017 00:00:00 GMT Novartis' new trial results demonstrate Cosentyx's ability to modify course of psoriasis http://www.drugdevelopment-technology.com/news/newsnovartis-new-trial-results-demonstrate-cosentyx-ability-to-modify-psoriasis-course-5768308 http://www.drugdevelopment-technology.com/news/newsnovartis-new-trial-results-demonstrate-cosentyx-ability-to-modify-psoriasis-course-5768308 Swiss-based healthcare company Novartis has reported positive results from the extension A2302E1 trial of Cosentyx (secukinumab), indicating the product's ability to modify the course of moderate-to-severe psoriasis with long-term and treatment-free … Wed, 22 Mar 2017 00:00:00 GMT Apexigen begins enrolment in APX005M combination therapy Phase I/II trial for melanoma http://www.drugdevelopment-technology.com/news/newsapexigens-apx005m-combination-therapy-phase-iii-trial-for-melanoma-begins-enrollment-5768572 http://www.drugdevelopment-technology.com/news/newsapexigens-apx005m-combination-therapy-phase-iii-trial-for-melanoma-begins-enrollment-5768572 Biopharmaceutical firm Apexigen has begun enrolling patients in a Phase I/II clinical trial of APX005M in combination with pembrolizumab (Keytruda) to treat metastatic melanoma. Wed, 22 Mar 2017 00:00:00 GMT Blueprint begins Phase I trial of BLU-667 to treat solid tumours with RET alteration http://www.drugdevelopment-technology.com/news/newsblueprint-begins-dosing-in-phase-i-trial-of-blu-667-to-treat-solid-tumours-with-ret-5767883 http://www.drugdevelopment-technology.com/news/newsblueprint-begins-dosing-in-phase-i-trial-of-blu-667-to-treat-solid-tumours-with-ret-5767883 Blueprint Medicines has begun the enrolment and dosing of patients in its Phase I clinical trial of BLU-667 to treat advanced solid tumours with RET alteration such as non-small-cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Wed, 22 Mar 2017 00:00:00 GMT Pharmatest to Host Seven Presentations at AACR in Washington, US http://www.drugdevelopment-technology.com/contractors/contract_research/pharmatest-services-pharma/presspharmatest-seven-presentations-aacr-washington-us.html http://www.drugdevelopment-technology.com/contractors/contract_research/pharmatest-services-pharma/presspharmatest-seven-presentations-aacr-washington-us.html Pharmatest Services has announced it will attend the annual meeting of American Association for Cancer Research (AACR) in Washington, US. Tue, 21 Mar 2017 10:51:00 GMT Ergomed begins Phase II trial of peprostat to control intraoperative surgical bleeding http://www.drugdevelopment-technology.com/news/newsergomed-begins-phase-ii-trial-of-peprostat-to-control-intraoperative-surgical-bleeding-5766941 http://www.drugdevelopment-technology.com/news/newsergomed-begins-phase-ii-trial-of-peprostat-to-control-intraoperative-surgical-bleeding-5766941 UK-based pharmaceutical company Ergomed has begun patient enrolment in a proof-of-concept Phase IIb clinical trial of peprostat to control intraoperative surgical bleeding. Tue, 21 Mar 2017 00:00:00 GMT Galena reports positive results from Phase I/IIa cancer trial of GALE-301 http://www.drugdevelopment-technology.com/news/newsgalena-reports-positive-results-from-phase-iiia-trial-of-gale-301-to-prevent-cancer-recurrence-5766935 http://www.drugdevelopment-technology.com/news/newsgalena-reports-positive-results-from-phase-iiia-trial-of-gale-301-to-prevent-cancer-recurrence-5766935 US-based biopharmaceutical firm Galena Biopharma has reported positive final results from the Phase I/IIa clinical trial of GALE-301 (E39) to prevent recurrence of ovarian and endometrial cancer. Tue, 21 Mar 2017 00:00:00 GMT Boehringer Ingelheim begins enrolment in Phase III trial of nintedanib to treat PF-ILD http://www.drugdevelopment-technology.com/news/newsboehringer-ingelheim-begins-enrollment-in-phase-iii-trial-of-nintedanib-to-treat-pf-ild-5767471 http://www.drugdevelopment-technology.com/news/newsboehringer-ingelheim-begins-enrollment-in-phase-iii-trial-of-nintedanib-to-treat-pf-ild-5767471 German pharmaceutical firm Boehringer Ingelheim has begun patient enrolment in the Phase III clinical trial of nintedanib (OFEV) to treat progressive fibrosing interstital lung disease (PF-ILD). Tue, 21 Mar 2017 00:00:00 GMT